HYPE ETF cumulative net inflow surpasses 100 million dollars, BNB ETF records no net inflow on its first trading day
Foresight News reports, according to SoSoValue data, on May 28th Eastern Time, HYPE spot ETF had a single-day total net inflow of 1.718 million US dollars, with a historical cumulative net inflow reaching 100 million US dollars. The total net asset value is 122 million US dollars, and HYPE's net asset ratio is 0.90%.
By product, Bitwise Hyperliquid ETF (BHYP) saw a single-day net inflow of 1.0178 million US dollars, with a historical cumulative net inflow of 57.6954 million US dollars; 21Shares Hyperliquid ETF (THYP) had a single-day net inflow of 700,200 US dollars, with a historical cumulative net inflow of 46.4336 million US dollars.
On the same day, VanEck BNB ETF (VBNB) was listed on Nasdaq. According to SoSoValue data, VBNB had no net inflow on its first day of listing, with a trading volume of 113,000 US dollars and a total net asset value of 995,000 US dollars. This ETF supports cash and in-kind creation and redemption, with a management fee rate of 0.39%.
Both HYPE and BNB are regarded by the market as assets related to trading infrastructure, but in the early performance of fund flows in the ETF market, the two have shown differences. The former represents the on-chain derivatives trading platform Hyperliquid, while the latter is associated with centralized exchange ecosystem assets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Retail Investors Flock to Space-themed ETF, SpaceX Leads Space Investment Craze Recalling Early AI Wave
Glassnode: Market Direction Unclear After Bitcoin Options Expiry
Trending news
MoreAccording to statistics released by the American Automobile Association, the average retail price of gasoline in the United States reached $4.35 per gallon on the day, a decrease of 4 cents from the previous day and 17 cents lower than a week ago. However, this price is still 46% higher than the level before the outbreak of the Iran conflict.
Trial data released by Mineralys Therapeutics, Inc. showed that its candidate drug Lorundrostat achieved significant results in reducing the urinary albumin-to-creatinine ratio (UACR).
